| Nov 15 |
XORTX Therapeutics files to sell 810,810 common shares for holders
|
| Oct 24 |
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
|
| Oct 18 |
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
|
| Oct 17 |
XORTX Therapeutics stock falls after pricing $1.5M capital raise
|
| Oct 17 |
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
|
| Oct 9 |
XORTX Initiates Precision Medicine Program
|
| Sep 13 |
XORTX Announces Results of Annual and Special Meeting of Shareholders
|
| Sep 12 |
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
|
| Sep 6 |
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
|
| Sep 3 |
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
|
